Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells

Cancer Gene Therapy

Volumn 15, Issue 2, 2008, Pages 73-84

  Zhang, X ^a   Zhao, P ^a   Kennedy, C ^a   Chen, K ^a   Wiegand, J ^a   Washington, G ^a   Marrero, L ^a   Cui, Y ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen specific CTL function; Antitumor immunity; Dendritic cells; Hematopoietic stem cells; Lentiviral vector; Renal cell carcinoma

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENTIVIRUS VECTOR; OLIGODEOXYNUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CARCINOMA IN SITU; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; EPITHELIUM TUMOR; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; KIDNEY CARCINOMA; LUNG TUMOR; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE ACTIVATION;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LENTIVIRUS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; STEM CELL TRANSPLANTATION; STEM CELLS;

MUS;

EID: 38349059202     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701108     Document Type: Article

References (55)

1. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3: 630-641.
2. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003; 21: 807-839.
3. Powell Jr DJ, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 2006; 177: 6527-6539.
4. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18538-18543.
5. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213.
6. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
7. Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L et al. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res 2003; 63: 9007-9015.
8. O'Neill D W, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004; 104: 2235-2246.
9. Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann NY Acad Sci 2003; 987: 180-187.
10. Baggers J, Ratzinger G, Young JW. Dendritic cells as immunologic adjuvants for the treatment of cancer. J Clin Oncol 2000; 18: 3879-3882.
11. Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC et al. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest 2002; 109: 1463-1470.
12. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517-1526.
13. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18: 245-273.
14. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199: 815-824.
15. Merad M, Sugie T, Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 2002; 99: 1676-1682.
16. Esslinger C, Chapatte L, Finke D, Miconnet I, Guillaume P, Levy F et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 2003; 111: 1673-1681.
17. Cui Y, Kelleher E, Straley E, Fuchs E, Gorski K, Levitsky H et al. Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. Nat Med 2003; 9: 952-958.
18. Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999; 5: 774-779.
19. Sotomayor EM, Borrello I, Tubb E, Rattis FM, Bien H, Lu Z et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999; 5: 780-787.
20. Borrello I, Pardoll D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 2002; 13: 185-193.
21. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001; 19: 145-156.
22. Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999; 59: 3340-3345.
23. Eggert AA, van der Voort R, Torensma R, Moulin V, Boerman OC, Oyen WJ et al. Analysis of dendritic cell trafficking using EGFP-transgenic mice. Immunol Lett 2003; 89: 17-24.
24. Cayeux S, Richter G, Becker C, Pezzutto A, Dorken B, Blankenstein T. Direct and indirect T cell priming by dendritic cell vaccines. Eur J Immunol 1999; 29: 225-234.
25. Ruedl C, Koebel P, Bachmann M, Hess M, Karjalainen K. Anatomical origin of dendritic cells determines their life span in peripheral lymph nodes. J Immunol 2000; 165: 4910-4916.
26. Cui Y, Golob J, Kelleher E, Ye Z, Pardoll D, Cheng L. Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood 2002; 99: 399-408.
27. Zhao P, Liu W, Cui Y. Rapid immune reconstitution and dendritic cell engraftment post-bone marrow transplantation with heterogeneous progenitors and GM-CSF treatment. Exp Hematol 2006; 34: 951-964.
28. Trono D. Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Therapy 2000; 7: 20-23.
29. Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999; 283: 682-686.
30. Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G et al. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA 1999; 96: 2988-2993.
31. Borrello I, Sotomayor EM, Cooke S, Levitsky HI. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther 1999; 10: 1983-1991.
32. Chen K, Chen L, Zhao P, Marrero L, Keoshkerian E, Ramsay A et al. FL-CTL assay: fluorolysometric determination of cell-mediated cytotoxicity using green fluorescent protein and red fluorescent protein expressing target cells. J Immunol Methods 2005; 300: 100-114.
33. Zhou G, Lu Z, McCadden JD, Levitsky HI, Marson AL. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med 2004; 200: 1581-1592.
34. Blazar BR, Krieg AM, Taylor PA. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood 2001; 98: 1217-1225.
35. Atkins H, Davies BR, Kirby JA, Kelly JD. Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy. Br J Cancer 2003; 89: 2312-2319.
36. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004; 5: 508-515.
37. Kondo M, Wagers AJ, Manz MG, Prohaska SS, Scherer DC, Beilhack GF et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol 2003; 21: 759-806.
38. Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH. Non-myeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Program) 2001; 1: 375-391.
39. Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 2002; 110: 185-192.
40. Hu HM, Poehlein CH, Urba WJ, Fox BA. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 2002; 62: 3914-3919.
41. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274.
42. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-2413.
43. Down JD, White-Scharf ME. Reprogramming immune responses: enabling cellular therapies and regenerative medicine. Stem Cells 2003; 21: 21-32.
44. Anderson Jr LD, Savary CA, Mullen CA. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. Blood 2000; 95: 2426-2433.
45. Saccardi R, Mancardi GL, Solari A, Bosi A, Bruzzi P, Di Bartolomeo P et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 2005; 105: 2601-2607.
46. Hanson HL, Kang SS, Norian LA, Matsui K, O'Mara LA, Allen PM. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors. J Immunol 2004; 172: 4215-4224.
47. Daro E, Pulendran B, Brasel K, Teepe M, Pettit D, Lynch DH et al. Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J Immunol 2000; 165: 49-58.
48. Basak SK, Harui A, Stolina M, Sharma S, Mitani K, Dubinett SM et al. Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood 2002; 99: 2869-2879.
49. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996; 184: 1953-1962.
50. Levitsky HI. Augmentation of host immune responses to cancer: overcoming the barrier of tumor antigen-specific T-cell tolerance. Cancer J 2000; 6(Suppl 3): S281-290.
51. Luznik L, Slansky JE, Jalla S, Borrello I, Levitsky HI, Pardoll DM et al. Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood 2003; 101: 1645-1652.
52. Emens LA, Armstrong D, Biedrzycki B, Davidson N, Davis-Sproul J, Fetting J et al. A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. Hum Gene Ther 2004; 15: 313-337.
53. Hess PR, Boczkowski D, Nair SK, Snyder D, Gilboa E. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother 2006; 55: 672-683.
54. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27: 195-201.
55. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007; 13: 1757-1761.